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Abstract
Vaccines have provided the most beneficial contribution to public health. Generating antigen specific antibody
responses and long lasting memory are crucial for the protective immunity offered by vaccination. Unfortunately, not
all individuals respond in the same manner to vaccine formulations. The microbiota is established during postnatal
development and remains relatively stable for long periods. Our understanding that the microbiota can have
beneficial effects on human health has led immunologists to investigate how these organisms may shape the innate
and adaptive immune responses of the host. In this review we examine the impact of the microbiota on the host
immune responses to vaccines and explore the possibility of how the commensal bacteria may act as natural
adjuvants to enhance systemic immune responses to vaccines.

Keywords: Microbiota; Vaccines; B cells; Innate immunity; Adaptive
immunity; Adjuvants; LPS

Introduction
Vaccination remains one of the most beneficial contributions of
biomedical science to public health where they have reduced the
burden of infectious disease by protecting the most vulnerable, young
infants and the aged [1]. Bacteria were once viewed as the nemesis of
human health as they were the cause of harmful and insidious
infectious diseases. However, it has only been in recent years that the
influence of the gut microbiota on human health has come to be truly
appreciated [2]. Disruption of the balance of microbial species within
human tissues can actually lead to inflammatory responses and disease
[3]. While the importance of commensal microorganisms in
preventing or alleviating certain diseases has been quite firmly
established, their potential role as an adjuvant for vaccination is
currently being explored and this topic will form the focus of the
review.

Compartmentalization of the microbiota
The “microbiota” refers to the wide variety of microorganisms
which colonise the human body as their natural habitat [4]. The
microbiota is established during postnatal development and a range of
factors influence the composition of the microflora including
gestational age, route of birth, infant diet, maternal diet and weight as
well as exposure to antibiotics early in life [4-6]. Antibiotics which are
used to treat infections caused by bacterial pathogens directly impact
on the diversity and function of the microbiota [6].
Mucosal surfaces of the skin, gut, respiratory and reproductive
tissues provide a physical barrier that limits access of microorganisms
to the underlying tissues. Each surface is colonised by a diverse range
of microbes and the stability of these niches will be influenced by a
continuous dialogue of communication between the microbes and the
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host structural, immunological, hormonal and nervous systems
networks [7-9]. It is evident that a primary role of the healthy
microbiota on the immune system is to reinforce barrier immunity and
to contain the microbes to the external mucosal surface. In the gut,
respiratory tract and reproductive system this is achieved through the
secretion of mucous and antimicrobial peptides by epithelial cells and
secretion of IgA (sIgA) across the epithelial barrier to the luminal
surface [7]. The gastrointestinal tract was the first tissue where
compartmentalisation of the microbiota was described [10]. The
stratification of microbes in the mucous layer overlying the intestinal
epithelial cells prevents contact between microbes and host cells.
Further, the production and secretion of antimicrobial peptides by
epithelial cells seeks to further control those organisms which reside in
the inner mucous layer, so as to ensure the integrity of the epithelial
barrier and tissue homeostasis [11].
Studies by Naik et al. revealed that the resident microflora of the
skin is compartmentalised in a manner which is independent of the
gut microflora. The skin microflora can control the balance of effector
and regulatory T cells in the skin tissue mediated by Myd88 and IL-1
receptor signalling [12]. Spontaneous skin inflammatory diseases in
humans such as atopic dermatitis, rosacea, and psoriasis have been
associated with dysbiosis of the skin microbiota. This study highlighted
that microbial products derived from the microflora may play a crucial
role in regulating immune responses at this site.
DNA sequencing of bacterial samples collected from various human
tissues has enabled scientists to identify the key resident species that
occupy tissue specific niches. Colonisation of these niches will be
influenced by environmental and genetic factors and the makeup of the
resident flora in various tissue niches may vary between groups of
people living in different areas of the world and their varied health
outcomes [13]. In the gut the dominant bacterial species include
Bacteroides, Prevotella and Ruminococcus and the two phyla which
form a majority of the human gut microbiota are Bacteroidetes and
Firmicutes [14]. The dominant bacterial taxa that colonize the skin

Volume 4 • Issue 2 • 1000150

Citation:

Benn N, Hoyne GF (2018) Role of the Gut Microbiota as a Natural Adjuvant for Vaccine. Immunotherapy (Los Angel) 4: 150. doi:

10.4172/2471-9552.1000150

Page 2 of 5
include Actinobacteria, Firmicutes and Proteobacteria. The vaginal
mucosa is dominated by Lactobacillus spp, while Fusobacteria spp,
Firmicutes and Proteobacteria are predominant within the oral cavity
[9].

Impact of the commensal flora on the immune system
The microbiome has a crucial role in the development of the
immune system in the neonatal period that is necessary to establish
lifelong host-microbial and immune homeostasis [15]. The prenatal
and perinatal developmental period is linked to the effects of
environmental factors (e.g. microbial exposure) that influence immune
and tissue maturation of the host [16]. Indeed early life exposures can
have important outcomes on susceptibility to disease in adult life and
this topic has been recently reviewed by Torow et al. [17]. Short chain
fatty acids produced by microbes can shape the adult immune system
[18,19]. Gomez de Augero et al. [15] identified that bacterial derived
metabolites produced by maternal gut derived commensal organisms
were transferred to the offspring via the breast milk and could be
detected in tissues of the offspring. The bacterial metabolites included
a range of ligands bound by the aryl hydrocarbon receptor (Ahr)
which is expressed by group 3 innate lymphoid cells (ILC3). These Ahr
ligands could induce expansion of the ILC3 cells that secrete IL-17 and
IL-22 which are key cytokines that play a crucial role in maintaining
barrier function within the intestine, by inducing the secretion of
antimicrobial peptides and to promote epithelial repair respectively.
Germ Free Mice (GFM) that develop without an intestinal flora
display defects in adaptive immune function. Colonization of GFM
with intestinal bacteria can promote maturation of mucosal and
systemic secondary lymphoid tissues [20]. In addition the development
of CD4+ regulatory T cells, Th17 cells and TCRγδ+ cells are deficient in
GFM indicating that the development of a range of adaptive immune
cell types rely on successful colonisation and maintenance of a stable
and diverse intestinal microflora [18-22].

Vaccination
The main aim of vaccination is to stimulate innate and adaptive
immune responses to microbial antigens to induce long lived memory
T and B cells. CD4+ Th helper cells elicited to the vaccine antigen can
provide help to antigen specific memory B cells and CD8+ T cells
[23-25]. The CD4+ Th cells provide help to B cells to generate
neutralizing antibodies that can efficiently bind and neutralise the
target pathogen to facilitate its removal. It was noted by Janeway that a
foreign antigen on its own was insufficient to elicit an adaptive
immune response [26]. Adjuvants have been used extensively with
vaccines to improve the potentially poor immune response
experienced when the vaccine is administered on its own [23]. The
main components of adjuvants were molecules derived from the
bacterial cells. The discovery of Pathogen Associated Molecular
Patterns (PAMPs) as the conserved elements of microbes and their
ability to bind to Pattern Recognition Receptors (PRRs) helped to
consolidate the view that PAMPS were a key element responsible for
the beneficial effects of adjuvants [27]. The PRRs can be located on the
cell surface or within the cytosol or endosomes of Antigen Presenting
Cells (APCs) to enable the innate immune system to distinguish
between extracellular versus intracellular pathogens [27,28]. APCs
activated by PAMPS undergo maturation for efficient antigen
processing and presentation; they can express co-stimulatory
molecules and secrete cytokines to help drive the adaptive immune
response [27]. Despite knowledge that adjuvants improve
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immunogenicity, the differential responses by groups of people around
the world to the same vaccine makes it difficult to identify ways to
ensure everyone mounts an effective response. A number of potential
explanations have been offered regarding the reason for the variability
to vaccine responses include: genetics, socioeconomic status and
nutritional intake [29]. The consideration of the gut microbiome as a
natural adjuvant, however, is one that is gaining traction in research,
and is offering relatively promising results.
The potential for adjuvants to exist naturally in the human body in
the context of the commensal organisms that constitute the microbiota
is exciting especially considering the benefits that vaccination has
provided to improvements in public health worldwide. To produce a
vaccine which has enhanced effects upon exposure to the natural tissue
environment of the host could potentially reduce production costs of
vaccines by eliminating the need to include an adjuvant, but the
vaccine would still retain the benefits of an improved health outcome
for the population. The generation of antigen specific antibodies
provide a link between the adaptive and innate immune response as
antibodies have a multifaceted role in effector activities including
neutralizing pathogens, to promote opsonisation and phagocytosis by
phagocytic cells such as macrophages, they function in complementmediated lysis of pathogens, or to direct antibody dependent cellular
cytotoxicity mediated by NK cells. Since many of the bacterial antigens
are conserved between symbiotic and commensal bacteria Zeng et al.
hypothesized that antibodies directed to symbiotic bacteria may be
beneficial in controlling systemic infections of pathogens [10]. In this
study the commensal gut bacteria were used to incite the production of
immunoglobulin G (IgG) antibodies, which, through opsonisation,
could eliminate pathogenic Gram-negative bacteria. One antigen
identified as a key inducer of an antibody response to bacteria was
Murein Lipoprotein (MLP). Using a mouse model it was shown that
recognition of MLP derived from commensal bacteria was dependent
on CD4+ T cells and Toll-like Receptor 4 (TLR4) expressions on B cells
to produce IgG that enabled the control of systemic Escherichia coli
and Salmonella infections [10]. The outcomes of this study highlighted
how bacteria in a localised area “the gut” are able to influence systemic
immune responses throughout the body. If commensal bacteria could
promote antibody production under homeostatic conditions, then
utilising this natural response generated to commensal bacteria could
in turn enhance antibody responses to vaccine antigens.
To further explore the relationship between the intestinal microflora
and the response to vaccination with a model antigen ovalbumin in
infant mice, Lamouse et al. treated mothers with antibiotics during
pregnancy and breastfeeding stages, and the effects on their offspring
to an immunization response was measured [30]. Pups derived from
antibiotic treated mothers showed changes in the relative abundance of
three main gut bacteria- Bacteroidetes, Enterobacteriaceae and
Firmicutes when compared to the control pups derived from nontreated mothers. Notably, antibiotic affected mice were reported to
harbour a higher prevalence of Enterobacteriaceae which can cause
inflammatory responses. Furthermore, while MyD88 expression was
consistent between the test and control population of adult mice, the
expression of key effector molecules important for gut homeostasis was
affected such as antimicrobial peptides (e.g. REGIIIγ, cryptidins), the
pattern recognition receptor NOD2 and downstream signalling
components (RIP2, RelMβ) [30]. These results suggest that without the
“normal microbiota”, immune regulation in the gut would be altered,
that could lead to dysbiosis or disease. Furthermore, the 7 day old mice
derived from antibiotic treated mothers when immunised with
ovalbumin (OVA) subcutaneously, displayed significantly reduced
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antibody titres to OVA, compared to the immunisation response of
aged matched pups derived from control mice. However,
immunisation of pups at 14 days of age saw no significant difference
between the two populations; potentially implicating a developmental
factor in the vaccine response. It was important to note that antibiotic
treatment per se had no demonstrable effect on total serum IgG levels
in the pups immunised at one week old, suggesting the reduced
antibody response to OVA was not due to any impact of antibiotics on
B cell development or function. Furthermore, GFM immunised with
the same vaccine at different ages had a minor but reproducible
decrease in OVA antibody titres, which were not accounted for by
developmental age. Colonisation of the GFM with intestinal bacteria
was able to reverse this deficit to OVA immunization [30]. While these
results do not prove that the microbiota actively acts as an adjuvant,
they certainly support the notion that a complete lack of, as well as an
alteration in, the normal gut microbiota can compromise vaccine
responses in mice.
A more comprehensive study by Oh et al. [31] supported the
positive association between the gut microbiota and the immune
response following vaccination with the Trivalent Influenza Virus
(TIV) vaccine. The study utilised wild type, germ-free and antibiotictreated mice to establish the fact that the gut microbiota does in fact
act as a natural adjuvant for the TIV and oral polio vaccines. Further
testing indicated that flagellin of the gut bacteria could activate the
Toll-like receptor 5 (TLR5) to promote an effective humoral response.
Following primary vaccination, the titre of vaccine-specific antibodies
and the frequency of plasma B cells was increased in wild-type mice as
compared to germ-free and antibiotic-treated mice after 7 days [31]. It
was also discovered that inoculation of flagellated, and not aflagellated,
E. coli restored the antibody response to flagellin experienced by
antibiotic-treated and germ-free mice. Furthermore, in terms of the
humoral response, a positive association was identified between the
presence of “normal” gut microbiota and improved memory B cell
response [31]. Interestingly, the same study observed that flagellin
could enhance the antibody response to the inactivated polio vaccine
that was delivered in the absence of an adjuvant. In contrast antibody
responses to other adjuvanted or live vaccinations such as yellow fever
17D were not affected in these mice [31]. Recognition of the gut
microbiota by the PRR nucleotide binding oligomerization domain
containing (NOD) 2 was identified to be important for the adjuvant
properties of the mucosal adjuvant cholera toxin when coadministered with the protein antigen Human Serum Albumin (HSA)
[32]. Mice carrying mutations in Nod2 or the downstream signalling
adaptor protein Ripk2 displayed impaired antibody responses to HSA.
Reconstitution of GFM mice with muramyl dipeptide a Nod2 ligand or
colonization with bacteria with Nod2 stimulatory activity was
sufficient to restore anti-HSA responses in vivo [32].
While the knowledge gained from this line of research is important
to elucidate the specific role of the microbiota in vaccine response, it is
necessary to consider whether similar results are observed in humans.
Rotavirus (RV) is largely implicated in the gastroenterological-related
mortality of children, particularly in locations where the efficacy of the
Rotavirus vaccination is reduced. Researchers were motivated to
identify if changes in the microbiome was a relevant contributing
factor to these associations to Rotavirus vaccine responses [33]. A 2017
study by Harris et al. compared the immune response to the Rotavirus
vaccine of a cohort of infants from Ghana and compared them to
infants from Netherlands. The results obtained by Harris et al. [33],
showed that the microbiome (as identified through faecal analysis) of
vaccine responders and non-responders were significantly different. It
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was also noted that the microbiome of responder children from both
Dutch and Ghanaian cohorts proved significantly more similar, in
terms of diversity, compared to non-responders. Analysis of bacterial
species revealed an increased prevalence of Bacteroidetes among
vaccine non-responders, while in responder children an increased
prevalence of Streptococcus bovis was observed. Conversely, a parallel
study conducted in Pakistan [34] noted that vaccine responders to the
Rotavirus vaccine (anti-RV IgA ≥ 20 IU/mL) harboured a significantly
higher Gram-negative to Gram-positive bacterial ratio, particularly
Serratia and E. coli species, compared to non-responders. This may be
related to what was identified by Zeng et al. [10] who noted that Gramnegative commensal gut bacteria enabled control of infection by E. coli
and other Gram-negative pathogens. Thus, if these Gram-negative
bacteria have a higher abundance in the gut of vaccine responders, the
immune system may have been primed through systemic action of
commensal bacteria and hence, mounted a better response to the
vaccination. It remains to be seen if this is anyway related to exposure
to flagellin or LPS as potential PAMPS that act as adjuvants to
stimulate vaccine mediated antibody responses. It is important to note
that LPS can vary from species to species of Gram negative bacteria
[35]. LPS derived from bacteroidetes species was demonstrated to have
an inhibitory capacity to stimulate inflammatory cytokines when
compared to LPS derived from E. coli [36].
Furthermore, when Harris et al. [34] compared with Dutch agematched counterparts (who experienced higher immunogenicity of the
vaccine) the Pakistani infants had lower abundances of Proteobacteria.
In addition, results from a study of Indian infants who responded to
the oral Rotavirus vaccine found that they were more likely than nonresponders to have more than one Enteropathogen as part of their
microbiota [37]. This trend of enteric and Gram-negative bacteria
specifically being associated with relatively improved immunogenicity
seems to support the fact that the composition of the microbiota may
impact the vaccine response in humans. As Harris et al. [33] found the
abundance of Bacteroidetes positively correlated with non-responder
status to the Rotavirus vaccine, one may hypothesise that the
immunogenic effects of Gram-negative bacteria occur only at a certain
degree of microbial abundance. These results will surely have
interesting implications as research develops to elucidate how specific
bacterial species may act to hinder or improve the systemic
immunological response to vaccines.
The specific mechanism of action regarding bacterial improvement
of vaccine responses has been addressed by Zhang et al. [38]. The study
sought to investigate whether mice could be protected against
Rotavirus and whether those with chronic infections could be cured.
In concordance with the results of the study by Oh et al. [31] it was
found that flagellin and its receptors were vital in the prevention and
cure of Rotavirus-infected mice. Moreover, TLR5 and the NOD-like
receptor C4, were important in responding to flagellin triggering the
production of IL-22 and 18, for each receptor respectively [38]. These
receptors, pathways and molecules enabled the immune system to
destroy cells that had been infected with Rotavirus and rescue mice
with chronic infections. The implication of these findings is that, in
addition to strengthening the argument that the microbial components
are important in the systemic immune response, it also provides an
alternative, potentially more effective, treatment for viral infections.

Shigella species are Gram negative bacteria that invade mucosal
tissues and cause bacillary dysentery or shigellosis in both humans and
non-human primates such as macaques. These animals are widely used
in pathogenesis and vaccine research. Seekatz et al. [39] observed that
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macaques from different geographical areas had distinct composition
of the faecal microflora. They observed that the Mauritian macaques
had a genetically distinct and highly diverse bacterial community in
the faecal microflora compared to non-Mauritian macaques. They also
observed that the two different macaque populations responded
differently to Shigella immunization. Both macaque populations could
generate antibody responses to Shigella but clinical shigellosis was only
observed among the non-Mauritian macaques [39]. This is further
evidence that the microbiota should be considered when developing
vaccinations.

Conclusion
In light of the discussion presented here the gut microbiota appears
to have the potential to act as an adjuvant for vaccination in some
contexts, but also may impair the immune response depending on the
specific composition and abundance of microbes present. Influenza
virus and Rotavirus are pathogens that can cause significant harm in
human populations. Yet there is hope in studying components of the
commensal bacteria (e.g. flagellin, LPS etc), through innate receptor
signalling and T and B cell activation, they could in future improve
responses to vaccines against these other pathogens. Notwithstanding
that there are many factors which can influence the response to
vaccination and that the role of the gut microbiota in such a response
is not easily elucidated, the studies discussed still provide relevant
insight into future directions of research. Furthermore, they enable one
to develop an appreciation for the microbiota; an entity which, when
truly understood, may improve the health outcomes of many
individuals around the world who have been disadvantaged simply due
to their place of birth and diet.
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